Molecule to Market: Inside the outsourcing space

The Latin American logistics leader

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jaqueline Escotero, Regional Vice President for Latin America at World Courier.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jaqueline, covering:

• The misconnections, characteristics and challenges of doing business in Latin America’s pharmaceutical sector.
• The immense complexity and level of responsibility involved in vaccine storage and distribution over the last year.
• Timeless lessons from a lifetime spent doing international business all over the world.
• A key trend that everyone in our sector needs to be prepared for in a post-pandemic world.

Jaqueline is responsible for the World Courier business in Latin America and is based in São Paulo, Brazil. She is an experienced executive, with 29 years of international experience in the healthcare industry, leading important roles in marketing, sales, training, government and external affairs, specialty logistics and customer service at major pharmaceutical and medical device companies. She holds an MBA in Strategic Marketing and Bachelor Degree in International Business. She is also the global Chairperson of WIN - “Women’s Impact Network” - at AmerisourceBergen, a global initiative, focused on over 40,000 employees.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

 

The opportunistic entrepreneur

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ross Burn, Chief Executive at CatSci.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ross, covering:

• Creating a successful business from an opportunistic AZ spin-out.
• Never being afraid to pivot in-line with the needs of the market and have big aims like becoming an innovative medicines development partner with a $1 billion valuation.
• The challenge of raising capital as an oversubscribed CRO with a 50% compound growth rate.

How the pandemic has helped put life sciences and pharma R&D on the map but also the work to be done to meet unmet needs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

The Floundering Founder, a lifetime of knowledge for as little as a pound/dollar.

In this special bonus episode of Molecule to Market, our host discusses his very first book launch ‘The Floundering Founder’ which is now available on Amazon and Kindle. 

Whilst you know him as the host of Molecule to Market, Raman has built up an impressive career in marketing, leadership and sector disciplines over the past 20+ years working within the global pharmaceutical and biotech outsourcing sector. Over the past twelve months of that career, Raman has spent an hour each day working on his latest achievement: ‘The Floundering Founder.’

The Floundering Founder gives 24 lessons to refocus your business and better yourself.  

With quick, simple lessons, The Floundering Founder can help you re-engineer your business and your life for sustainable, long-term success.

In twenty-four bite-sized lessons that fit any schedule, you’ll learn to navigate forward with renewed intentionality and purpose.

Make no mistake, this book isn’t fictional. You will relive the close and personal revelations of starting and scaling a business and how ramarketing has grown to be one of the most fast-growing global marketing agencies. 

To purchase visit:

UK link is here

US link is here

We would love to hear what you think of the book! Please write us a review to let us know what you think in the review section.

From Pharmacy to $1B family-owned CDMO

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Peter Soelkner, Managing Director at Vetter.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Peter, covering:

• The fascinating and humble origin story of one of the world’s most well respected sterile filling specialists.
• Peter’s journey of leading Vetter in becoming a $1bn, 5500 person family-owned CDMO...alongside a fellow Managing Director.
• How the DNA of a culture becomes a critical competent of global business growth and consistent client delivery.
• Key future industry trends, including the challenge of preparing for the ‘colourful scenery of biotechs in the next 10 years’ - meaning the need to have the flexibility to deal with ultra orphan drug products and high volume products needing high speed lines.

Peter Soelkner has been a Managing Director of Vetter Pharma-Fertigung GmbH & Co. KG since June 2008. In 2009, he was also appointed Managing Director of Vetter Pharma International GmbH, the company’s marketing and sales organization. Soelkner graduated from the University of Dortmund, Germany, in 1992 with a degree in chemical engineering and earned an MBA from Columbia University, New York, in 2001. Before joining Vetter, he held positions in Germany and North America at Sartorius AG and Sartorius North America Inc., in R&D, marketing, key account management, and general management roles. At Vetter, from 2003 to 2007, Soelkner managed the company’s key account program and global end-to-end supply chain. He left the company for a year to serve as Vice President of global key account management at Sartorius Stedim Biotech (USA) before returning to Vetter in 2008.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

Roundtable: M&A trends in CDMO

In this special roundtable episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

Jean-Jacques Mondoloni, Managing Partner WOMBAT CAPITAL

Mark Quick, Executive Vice President Corporate Development at Recipharm

Gerry Cox, Vice President at Pace Life Sciences

Your host, Raman Sehgal, discusses M&A trends in the pharmaceutical and biotechnology supply chain, covering:

• What a real-life M&A deal in outsourcing looks like from the buyer, seller and advisor angle.
• How the dynamics of M&A have changed over the last decade given the fragmented marketplace alongside increased funding, PE-interest and a pandemic spotlight now on the sector.
• Dizzying multiples, the fight for assets and key factors driving deals and valuations in contract services.
• Predictions from the panel around the future of deal flow in the outsourcing space... will the current velocity continue?

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

The UK’s hidden life science gem

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Michelle Duggan, Inward Investment Manager, Invest North East England.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Michelle, covering:

• Why is North East England becoming a UK hot spot for Health and Life Sciences.
• Collaborating and breaking down barriers to help create a super cluster of life sciences.
• The academic and industrial heartbeat that makes the region so attractive to CDMOs and major supply chain players.

Michelle Duggan has been an inward investment manager at invest North East England since January 2021. In 2016 to 2020 she was previously appointed as Partnership manager of Newcastle University where she was responsible for cultivating and maintaining relationships among business partners. 

 

Her devotion to the North East is unmatched across her extensive career. With her other previous position as economic advisor at North East Local Enterprise Partnership she helped place where businesses invest, grow and prosper - delivering more and better jobs for everyone.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

 

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

 

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

Meet the potent powder expert

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Chris Eccles, Chief Executive Officer at ChargePoint Technology. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Chris, covering:

• The journey from a management buy-out (MBO) to running a £20m,100-person, global business.
• Benefit of investing in technology within sterile environments to avoid cross contamination and prevent expensive downtime.
• A perfect storm of market factors that are driving demand for ChargePoint and its products, including the explosion of facility investments in the CDMO space.
• The shift towards single use technologies yet the need to combat plastic usage. And how sustainability will become a core business issue and a major valuation metric for buyers.
• An inside look into the virtual process of ChargePoint’s recent acquisition by Arcline Investment Management and the dizzying level of buyers that were in the running for the fast-growing business.

Chris has managed the global business expansion of ChargePoint across all functions including offices based in the UK, Europe, America and Far East. His background in manufacturing management and precision engineering was instrumental in determining the strategy to outsource manufacturing through strategic acquisitions and equipment investments, including the investment in cleanroom technology and disposable manufacturing processes in 2019 and the managed recruitment of technical resources.

As CEO of ChargePoint, Chris has developed a strong positive culture within ChargePoint, focussed on honesty, integrity, and quality which is ultimately reflected in customer satisfaction, employee retention. And the recent successful acquisition of ChargePoint by Arcline Investment Management.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

Physician. Scientist. Entrepreneur.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Go van Dam, CEO & Founder at TRACER.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Go, covering:

• The value of micro-dosing and fluorescent imaging in small patient populations at the preclinical proof of concept phase, and the benefits to investors, biotech and big pharma.
• The journey of stepping out of the operating theatre and into the boardroom. Taking an idea from the academic breeding ground and scaling into an industrial level so it has greater application.
• How the academia and industry ecosystem can collaborate, share and partner for the greater good.
• The need to observe, talk and learn from others. And it’s OK to copy and paste what you like in others.

Prof. Go van Dam is the CEO and Co-Founder of TRACER, a Clinical Research Organisation specialising in generating fast and accurate in-human data with nuclear and optical molecular imaging techniques, even before the classical Phase I-III studies. Go is seen as a pioneer in the optical imaging field with groundbreaking research to his name. 

 

Go originated as a surgeon oncologist and professor of Surgery at Groningen University. He trained at Harvard, the Mayo Clinic and NCI. Go executed and published the 1st in-human application of targeted fluorescence imaging in 2011 (Nature Medicine) and published more than 140 papers predominantly about clinical translation of innovative targeted optical molecular imaging. He currently focuses on utilising his validated optical imaging expertise in the life sciences industry to reduce R&D innovation costs, shorten time-to-market, and increased efficiency for innovative drug development.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at tryzymewire.com

 

Hollywood DVDs to biotech drugs

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Devendra Mishra, Executive Director and Founder at Bio Supply Management Alliance (BSMA).

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Devendra, covering:

• Being at the birth of biotech becoming a business and creating a network of 10k+ supply chain professionals.
• How we have just been through the most creative and productive period in healthcare in the last 100 years. Government bodies, private companies and academia collaborating to break down barriers and accelerate growth.
• The similarities of developing a movie and developing a new drug product. And what the life science supply chain can learn from digital collaboration and data analytics that occur in Hollywood.

Devendra is an internationally recognized authority on supply chain management thinking and practice. For two decades he has been committed to the adoption of disruptive technologies in media and entertainment as well as life sciences as an adjunct professor of Supply Chain Management at Pepperdine University.

 

Since 2004, the Mission of BSMA has been to advance the supply chain of Life Science through collaboration and adoption of technology. Positioned in the USA, Europe and India, its members are all the major biotech and pharma companies of the world.

 

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

 

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

 

We are also proudly supported by Zymewire which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com 

 

The big pharma sourcing specialist

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Daniel Hogan, External Manufacturing Team Lead for the Americas at Bayer Pharmaceuticals.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Daniel, covering:

• Managing a portfolio of 30-50 CMO partners across OSD, aerosols, topicals and liquids. And why due diligence and careful CMO selection is vital given its 10 x harder to exit a site.
• Some of the fundamental differences and similarities between sourcing as a big pharma and a small biotech.
• What good and bad relationships look like with an outsourced partner.
• The proliferation and availability of vendors in the outsourcing space. And why there is always room for CDMOs/CMOs with novel capabilities.
• Timeless advice for CDMOs/CMOs/CPOs in building relationships and revenue with big pharma.

With almost 20 years in the sector, Dan’s technical knowledge encompasses diverse pharmaceutical dosage forms with experience manufacturing and formulating a wide range of products for oral, topical, and parenteral administration. He thrives on contributing to complex products with the potential to cure people of disease, enabling them to lead lives of health and wellness.

Leading a team of experienced engineers responsible for the technology interface between Bayer and Contract Manufacturing Organizations (CMOs), Dan currently manages the manufacturing of a diverse dosage, multimillion-dollar product portfolio while providing guidance on activities such as process optimization, technology transfer from Bayer research and development to CMOs and validation of processes at commercial scale at various CMOs.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is funded by ramarketing. An international content, design and digital agency that helps companies in life sciences get noticed.

We are also proudly supported by Zymewire, which is the leader in actionable sales intelligence for life science Business development professionals. In fact, thousands of life science BD professionals start their day with sales signals from Zymewire. Learn more at - zymewire.com